295 Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): updated results of a randomized phase II trial

C.Schlichting; H.Forstbauer; H.J.Schmoll; A.Grothey; K.Jordan; O.Kellner; C.Constantin; G.Dietrich; H.Kroening; L.Mantovani

首页> 外文期刊>European Journal of Cancer Supplements >295 Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): updated results of a randomized phase II trial

【24h】

295 Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): updated results of a randomized phase II trial

机译：295卡培他滨加伊立替康（CAPIRI）与卡培他滨加奥沙利铂（CAPOX）作为晚期结直肠癌（ACRC）的一线治疗：一项II期随机试验的更新结果

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2003年第5期|共2页
作者
C.Schlichting; H.Forstbauer; H.J.Schmoll; A.Grothey; K.Jordan; O.Kellner; C.Constantin; G.Dietrich; H.Kroening; L.Mantovani;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial [J] . Clemens Giessen, Ludwig Fischer von Weikersthal, Axel Hinke, BMC Cancer . 2011,第1期

机译：卡培他滨加贝伐单抗（Cape-Bev）与卡培他滨加伊立替康+贝伐单抗（CAPIRI-Bev）在转移性结直肠癌一线治疗中的随机，III期试验：AIO KRK 0110 Trial / ML22011试验
2. Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable|[sol]|metastatic colorectal cancer (mCRC) [J] . J Souglakos, N Ziras, S Kakolyris, British Journal of Cancer . 2012,第3期

机译：CAPIRI（卡培他滨，伊立替康）加贝伐单抗与FOLFIRI（亚叶酸，5-氟尿嘧啶，伊立替康）加贝伐单抗的II期随机试验作为一线治疗不可切除的结肠癌（mCRC）患者
3. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer [J] . Dimitrios Pectasides, Vasilios Karavasilis, George Papaxoinis, BMC Cancer . 2015,第1期

机译：Ⅲ期随机临床试验比较了卡培他滨和奥沙利铂（CAPOX）联合5-氟尿嘧啶，亚叶酸和奥沙利铂（改良的FOLFOX6）联合治疗高危II期或III期大肠癌患者的辅助治疗
4. Electrocheiiiotherapy of Colorectal Liver Metastases-Trial Update [C] . I. Edhemovic, E. Brecelj, A. Ivanecz World Congress on Electroporation and Pulsed Electric Fields in Biology, Medicine and Food Environmental Technologies . 2016

机译：结直肠肝转移的电杂化 - 试验更新
5. A randomized phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial [O] . Clemens Giessen, Ludwig Fischer von Weikersthal, Axel Hinke, 2011

机译：卡培他滨加贝伐单抗（Cape-Bev）与卡培他滨加伊立替康+贝伐单抗（CAPIRI-Bev）在转移性结直肠癌一线治疗中的随机III期试验：AIO KRK 0110 Trial / ML22011试验
6. A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial [O] . Teschendorf Christian, Sieber Markus, Denzlinger Claudio, 2011

机译：卡培他滨加贝伐单抗（Cape-Bev）与卡培他滨加伊立替康+贝伐单抗（CAPIRI-Bev）在转移性结直肠癌一线治疗中的随机III期试验：AIO KRK 0110 Trial / ML22011试验

295 Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): updated results of a randomized phase II trial

著录项

引文网络

相似文献

相关主题

期刊订阅